CD33_PGx6_Score Predicts Gemtuzumab Ozogamicin Response in Childhood Acute Myeloid Leukemia: A Report From the Children’s Oncology Group

PURPOSE: The US Food and Drug Administration recently announced reapproval of gemtuzumab ozogamicin (GO) for treatment of CD33-positive acute myeloid leukemia (AML), thus opening up opportunities to develop strategies for effective use of GO. In light of our recent report showing prognostic signific...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:JCO Precis Oncol
Egile Nagusiak: Chauhan, Lata, Shin, Miyoung, Wang, Yi-Cheng, Loken, Michael, Pollard, Jessica, Aplenc, Richard, Hirsch, Betsy A., Raimondi, Susana, Ries, Rhonda E., Bernstein, Irwin D., Gamis, Alan S., Alonzo, Todd A., Meshinchi, Soheil, Lamba, Jatinder K.
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: American Society of Clinical Oncology 2019
Gaiak:
Original Report
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC7446480/
https://ncbi.nlm.nih.gov/pubmed/32914031
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/PO.18.00387
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak